课题基金 / 基金详情

Elabela通过调控CMG2/Akt/GPX4铁死亡信号在高血压血管纤维化及血管损伤修复中作用机制研究

批准号:
92168117
项目类别:
重大研究计划
资助金额:
80.0 万元
负责人:
钟久昌
依托单位:
学科分类:
血管损伤、修复、重构和再生
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
钟久昌

项目摘要

结项摘要

钟久昌的其他基金

相似基金

相关文献

中文摘要
血管纤维化重构损伤是导致高血压心脑血管事件发生的病理生理学基础。我们前期研究提示,高血压状态下CMG2水平下调,伴有Apelin下调和血管损伤(FASEB J. 2021; Hypertension 2017),但其机制不明。已证实Elabela(ELA)为Apelin受体另一个重要配体,参与心血管功能调控。为此我们提出假说,ELA通过调控CMG2及其下游PI3K/Akt信号,改善血管铁死亡信号,减轻高血压血管纤维化重构和功能损伤。本课题拟利用SHR高血压大鼠、ELA过表达、CMG2KO小鼠结合Ang II微泵及TAC术制备高血压血管损伤模型,采用ELA-32、Lenti-CMG2和铁死亡抑制剂Fer-1开展体内外实验,探讨ELA对高血压CMG2/Akt/NRF2、SLC7A11/GPX4铁死亡信号及脂质过氧化、炎症及纤维化重构的影响,为确立ELA作为高血压血管损伤早期防治新靶点提供科学依据。
英文摘要
Hypertension is a common vascular disease with high morbidity and mortality all over the world. Vascular fibrosis and remodeling injury are the pathophysiological basis of cardiovascular and cerebrovascular events in patients with hypertension. Apelin receptor APJ has been shown to be activated by a novel endogenous peptide ligand known as Elabela (ELA, also called Toddler or Apela), with an important role in cardiovascular development and function. Activation of APJ by its cognate peptide ligand ELA induces a wide range of physiological effects, including anti-hypertension, positive inotropic action, diuresis, anti-remodeling, anti-inflammatory, antifibrotic and cardiorenal protection. Our previous studies have demonstrated that there were marked downregulated levels of capillary morphogenesis gene 2 (CMG2) and Apelin during hypertension, accompanied by vascular injury and dysfunction (FASEB J. 2021; Hypertension 2017), but underlying mechanisms remain largely unknown. The ELA-APJ axis has been shown to involve in vascular injury and repairment. Therefore, we speculated that ELA may prevent ferroptosis in vascular tissue and improve vascular fibrosis and structural and functional damage in hypertension by modulating the CMG2/PI3K/Akt signaling. In this project, hypertensive SHR rats, ELA overexpression and CMG2 knockout mice were used combined with Ang II osmotic minipump and TAC operation to prepare hypertensive vascular injury animal models. Recombinant lenti-CMG2 and ferroptosis inhibitor Fer-1 were used to carry out in vitro and in vivo intervention experiments and to systematically explore the effects of ELA on ferroptosis, lipid peroxidation and inflammation and fibrotic remodeling of hypertensive animal model by regulating the CMG2/Akt/Nrf2 and SLC7A11/GPx4 signaling, providing scientific basis for establishing ELA as a new target for early prevention and treatment of hypertensive vascular injury.
高血压靶器官损害防治工作难以突破的根本问题是血管纤维化重构及损伤再生修复。通过各种途径逆转血管重构损伤将成为抗高血压治疗的一个重要策略。已证实Elabela(ELA)参与心血管功能调控,但其机制未明。本课题拟利用自发性高血压大鼠(SHR)、AngII微泵诱导的高血压小鼠,采用ELA-32、铁死亡抑制剂Fer-1开展体内外干预实验,系统探讨ELA对高血压CMG2/Akt/NRF2、SLC7A11/GPX4铁死亡信号及脂质过氧化、血管结构功能损伤的影响。研究发现,与正常对照小鼠相比,高血压小鼠ELA、SIRT7、GPX4表达明显下调,而血管纤维化重构损伤明显。在高血压和血管钙化状态下血管组织中铁离子浓度、pSTAT3磷酸化及ROS生成则增加。ELA-32干预治疗后高血压小鼠血管组织中NRF2和GPX4水平上调,而铁离子、SLC7A11、CTGF、铁死亡和脂质过氧化损伤明显得到减轻。ELA和Fer-1治疗后高血压小鼠心血管纤维化重构和功能损伤明显改善,伴有IL-6/ STAT3信号的下调,而NRF2/GPX4表达升高。在体外培养的大鼠血管外膜成纤维细胞(AFs)中,DOX刺激明显抑制 AFs 细胞增殖和迁移,增加LDH释放,减少AFs 铁死亡和凋亡,伴随KLF15和铁死亡抑制因子Nrf2、GPX4、GSH水平下降。ELA-32干预可明显减轻DOX诱导的AFs 细胞铁死亡,减少 LDH 释放,提高 AFs 细胞活力,伴有KLF15、GPX4表达增加。Elabela显著抑制血管平滑肌细胞中的成骨分化和钙沉积,并可逆转高磷酸盐诱导的铁硫蛋白FDX1表达的增加。值得关注的是,Elabela通过维持线粒体膜电位,抑制线粒体分裂,减少线粒体ROS产生以及促进ATP水平,大大减轻了线粒体功能障碍和血管钙化(IMeta 2024; Free Radic Biol Med 2022;EBioMedicine 2024;Apoptosis 2024;Mol Med 2024),提示Elabela具有一定的抗铁死亡、抗氧化及抗纤维化及改善血管钙化功效。基于Elabela和铁死亡信号为药物新靶点开发新型药物,对于高血压靶器官损伤的早期预警、延缓血管钙化进展、减少高血压心血管事件的发生具有极为重要的临床意义,具有较好的应用前景。
SIRT7因子调控FDX1/SLC31A1铜死亡信号在高血压线粒体功能障碍及心肌重构损伤中的作用及机制
  • 批准号:
    82370432
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    钟久昌
  • 依托单位:
Elabela/Apelin-APJ轴在调控SIRT6/ku80信号和心脏衰老中的作用及其机制
  • 批准号:
    91849111
  • 项目类别:
    重大研究计划
  • 资助金额:
    50.0万元
  • 批准年份:
    2018
  • 负责人:
    钟久昌
  • 依托单位:
miRNA-122介导血管外膜APLN-AMPK自噬信号调控在高血压血管重构损伤的作用研究
  • 批准号:
    81770253
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2017
  • 负责人:
    钟久昌
  • 依托单位:
国内基金
海外基金